Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, Extranodal NK-T-Cell 2TMB-H 1Recurrence 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1

Interventions

10-propargyl-10-deazaaminopterin 12Cyclophosphamide 8Prednisone 7belinostat 6Vincristine 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Doxorubicin 6Brentuximab Vedotin 5romidepsin 4mogamulizumab 4darinaparsin 4Vitamin B 12 4Gemcitabine 4Folic Acid 4selinexor 3denileukin diftitox 3Nivolumab 3Injections 3Bendamustine Hydrochloride 3tislelizumab 2tipifarnib 2tenalisib 2duvelisib 2Rituximab 2Lenalidomide 2HBI-8000 2Fenretinide 2E7777 fusion protein 2AFM13 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell, Peripheral × IMC-001 × Clear all
NCT03999658 2023-05-01

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Sorrento Therapeutics, Inc.

Phase 2 Withdrawn
GastrointestinalLymphoid

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Cholangiocarcinoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡